{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:08:40Z","timestamp":1789038520858,"version":"build-2803163510"},"reference-count":163,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente"],"award-info":[{"award-number":["Ricerca Corrente"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"DOI":"10.1007\/s40291-026-00879-w","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:18:00Z","timestamp":1789035480000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Amyloid-\u03b2 PET Radioligands in Alzheimer\u2019s Disease: From Plaque Detection to Biomarker-Guided Patient Stratification and Therapeutic Monitoring"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-7858","authenticated-orcid":false,"given":"Simone","family":"Lista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4423-5496","authenticated-orcid":false,"given":"Luca","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3908-0290","authenticated-orcid":false,"given":"Enzo","family":"Emanuele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9758-8239","authenticated-orcid":false,"given":"Susana","family":"L\u00f3pez-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1131-4315","authenticated-orcid":false,"given":"Giusy Ylenia","family":"Cisale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6512-611X","authenticated-orcid":false,"given":"Piercarlo","family":"Minoretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1499-5718","authenticated-orcid":false,"given":"Francesco","family":"Garaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2309-3583","authenticated-orcid":false,"given":"Alejandro","family":"Santos-Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"issue":"9","key":"879_CR1","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/aps.2017.28","volume":"38","author":"GF Chen","year":"2017","unstructured":"Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, et al. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin. 2017;38(9):1205\u201335. https:\/\/doi.org\/10.1038\/aps.2017.28.","journal-title":"Acta Pharmacol Sin"},{"key":"879_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-med-042921-023749","volume":"74","author":"B Hyman","year":"2023","unstructured":"Hyman B. All the tau we cannot see. Annu Rev Med. 2023;74:503\u201314. https:\/\/doi.org\/10.1146\/annurev-med-042921-023749.","journal-title":"Annu Rev Med"},{"issue":"4","key":"879_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"879_CR4","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr.","year":"2024","unstructured":"Jack CR Jr., Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association workgroup. Alzheimers Dement. 2024;20(8):5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"879_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2967\/jnmt.125.271835","volume":"54","author":"T Skyles","year":"2026","unstructured":"Skyles T, Bouchal SM, Giarratana A, Wengler J, Hart I, Greig E, et al. PET imaging in Alzheimer disease in the era of antiamyloid therapy in the United States: clinical utility, quantification, and policy landscape. J Nucl Med Technol. 2026;54(1):10\u20137. https:\/\/doi.org\/10.2967\/jnmt.125.271835.","journal-title":"J Nucl Med Technol"},{"issue":"2","key":"879_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/WCO.0000000000001471","volume":"39","author":"G Mathoux","year":"2026","unstructured":"Mathoux G, Harput E, Peretti DE, Boccalini C, Garibotto V. Clinical amyloid and tau positron emission tomography imaging in Alzheimer\u2019s disease: image interpretation in the era of anti-amyloid therapies. Curr Opin Neurol. 2026;39(2):161\u20137. https:\/\/doi.org\/10.1097\/WCO.0000000000001471.","journal-title":"Curr Opin Neurol"},{"issue":"8100","key":"879_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41586-025-10018-w","volume":"650","author":"H Zetterberg","year":"2026","unstructured":"Zetterberg H, Bendlin BB. Biofluid biomarkers in Alzheimer\u2019s disease and other neurodegenerative dementias. Nature. 2026;650(8100):49\u201359. https:\/\/doi.org\/10.1038\/s41586-025-10018-w.","journal-title":"Nature"},{"key":"879_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/bs.acc.2022.09.006","volume":"112","author":"J Simren","year":"2023","unstructured":"Simren J, Elmgren A, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer\u2019s disease. Adv Clin Chem. 2023;112:249\u201381. https:\/\/doi.org\/10.1016\/bs.acc.2022.09.006.","journal-title":"Adv Clin Chem"},{"key":"879_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2026.103058","volume":"117","author":"W Fu","year":"2026","unstructured":"Fu W, Ho PC. Blood-based biomarkers for Alzheimer\u2019s disease: advances in early detection and monitoring of age-related neurodegeneration. Ageing Res Rev. 2026;117:103058. https:\/\/doi.org\/10.1016\/j.arr.2026.103058.","journal-title":"Ageing Res Rev"},{"issue":"6","key":"879_CR10","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1515\/cclm-2023-1434","volume":"62","author":"B Arslan","year":"2024","unstructured":"Arslan B, Zetterberg H, Ashton NJ. Blood-based biomarkers in Alzheimer\u2019s disease: moving towards a new era of diagnostics. Clin Chem Lab Med. 2024;62(6):1063\u20139. https:\/\/doi.org\/10.1515\/cclm-2023-1434.","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"879_CR11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):280\u201392. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.003.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"879_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-01820-6","volume":"17","author":"R Ismail","year":"2020","unstructured":"Ismail R, Parbo P, Madsen LS, Hansen AK, Hansen KV, Schaldemose JL, et al. The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer\u2019s disease: a longitudinal PET study. J Neuroinflamm. 2020;17(1):151. https:\/\/doi.org\/10.1186\/s12974-020-01820-6.","journal-title":"J Neuroinflamm"},{"issue":"1","key":"879_CR13","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/brain\/awaa395","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Ossenkoppele R, Kvartsberg H, Brinkmalm A, Mattsson-Carlgren N, et al. Untangling the association of amyloid-beta and tau with synaptic and axonal loss in Alzheimer\u2019s disease. Brain. 2021;144(1):310\u201324. https:\/\/doi.org\/10.1093\/brain\/awaa395.","journal-title":"Brain"},{"issue":"3","key":"879_CR14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(18)30028-0","volume":"17","author":"BA Gordon","year":"2018","unstructured":"Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer\u2019s disease: a longitudinal study. Lancet Neurol. 2018;17(3):241\u201350. https:\/\/doi.org\/10.1016\/S1474-4422(18)30028-0.","journal-title":"Lancet Neurol"},{"issue":"4","key":"879_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2016.5755","volume":"74","author":"C Xia","year":"2017","unstructured":"Xia C, Makaretz SJ, Caso C, McGinnis S, Gomperts SN, Sepulcre J, et al. Association of in vivo [18F]AV-1451 tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease. JAMA Neurol. 2017;74(4):427\u201336. https:\/\/doi.org\/10.1001\/jamaneurol.2016.5755.","journal-title":"JAMA Neurol"},{"key":"879_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.nicl.2018.01.019","volume":"18","author":"SP Caminiti","year":"2018","unstructured":"Caminiti SP, Ballarini T, Sala A, Cerami C, Presotto L, Santangelo R, et al. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. Neuroimage Clin. 2018;18:167\u201377. https:\/\/doi.org\/10.1016\/j.nicl.2018.01.019.","journal-title":"Neuroimage Clin"},{"issue":"Pt 5","key":"879_CR17","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016;139(Pt 5):1551\u201367. https:\/\/doi.org\/10.1093\/brain\/aww027.","journal-title":"Brain"},{"issue":"11","key":"879_CR18","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41583-018-0067-3","volume":"19","author":"W Jagust","year":"2018","unstructured":"Jagust W. Imaging the evolution and pathophysiology of Alzheimer disease. Nat Rev Neurosci. 2018;19(11):687\u2013700. https:\/\/doi.org\/10.1038\/s41583-018-0067-3.","journal-title":"Nat Rev Neurosci"},{"issue":"8","key":"879_CR19","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/s41591-023-02476-4","volume":"29","author":"ECB Johnson","year":"2023","unstructured":"Johnson ECB, Bian S, Haque RU, Carter EK, Watson CM, Gordon BA, et al. Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer\u2019s disease. Nat Med. 2023;29(8):1979\u201388. https:\/\/doi.org\/10.1038\/s41591-023-02476-4.","journal-title":"Nat Med"},{"issue":"5","key":"879_CR20","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41591-025-03565-2","volume":"31","author":"HS Oh","year":"2025","unstructured":"Oh HS, Urey DY, Karlsson L, Zhu Z, Shen Y, Farinas A, et al. A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer\u2019s disease. Nat Med. 2025;31(5):1592\u2013603. https:\/\/doi.org\/10.1038\/s41591-025-03565-2.","journal-title":"Nat Med"},{"issue":"1","key":"879_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70986","volume":"22","author":"JM Burns","year":"2026","unstructured":"Burns JM, Alford S, Coppinger J, Jimenez-Mausbach M, Ray S, Pandey H, et al. Early Alzheimer\u2019s diagnosis: U.S. primary care physicians and use of blood biomarkers. Alzheimers Dement. 2026;22(1):e70986. https:\/\/doi.org\/10.1002\/alz.70986.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"879_CR22","first-page":"268","volume":"8","author":"L Filippi","year":"2018","unstructured":"Filippi L, Chiaravalloti A, Bagni O, Schillaci O. (18)F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer\u2019s disease. Am J Nucl Med Mol Imaging. 2018;8(4):268\u201381.","journal-title":"Am J Nucl Med Mol Imaging."},{"issue":"1","key":"879_CR23","doi-asserted-by":"publisher","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"A Serrano-Pozo","year":"2011","unstructured":"Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1(1):a006189. https:\/\/doi.org\/10.1101\/cshperspect.a006189.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"879_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s13311-016-0474-y","volume":"14","author":"K Anand","year":"2017","unstructured":"Anand K, Sabbagh M. Amyloid imaging: poised for integration into medical practice. Neurotherapeutics. 2017;14(1):54\u201361. https:\/\/doi.org\/10.1007\/s13311-016-0474-y.","journal-title":"Neurotherapeutics"},{"key":"879_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/B978-0-12-394816-8.00002-7","volume":"64","author":"AD Cohen","year":"2012","unstructured":"Cohen AD, Rabinovici GD, Mathis CA, Jagust WJ, Klunk WE, Ikonomovic MD. Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol. 2012;64:27\u201381. https:\/\/doi.org\/10.1016\/B978-0-12-394816-8.00002-7.","journal-title":"Adv Pharmacol"},{"issue":"2","key":"879_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"JRCR Jack","year":"2013","unstructured":"Jack JRCR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207\u201316. https:\/\/doi.org\/10.1016\/S1474-4422(12)70291-0.","journal-title":"Lancet Neurol"},{"issue":"9","key":"879_CR27","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367(9):795\u2013804. https:\/\/doi.org\/10.1056\/NEJMoa1202753.","journal-title":"N Engl J Med"},{"issue":"4","key":"879_CR28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357\u201367. https:\/\/doi.org\/10.1016\/S1474-4422(13)70044-9.","journal-title":"Lancet Neurol"},{"issue":"5","key":"879_CR29","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Scholl","year":"2016","unstructured":"Scholl M, Lockhart SN, Schonhaut DR, O\u2019Neil JP, Janabi M, Ossenkoppele R, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971\u20132. https:\/\/doi.org\/10.1016\/j.neuron.2016.01.028.","journal-title":"Neuron"},{"issue":"8","key":"879_CR30","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669\u201378. https:\/\/doi.org\/10.1016\/S1474-4422(12)70142-4.","journal-title":"Lancet Neurol"},{"issue":"1","key":"879_CR31","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jalz.2013.01.002","volume":"9","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association. Alzheimers Dement. 2013;9(1):e1-16. https:\/\/doi.org\/10.1016\/j.jalz.2013.01.002.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"879_CR32","doi-asserted-by":"publisher","first-page":"476","DOI":"10.2967\/jnumed.113.120618","volume":"54","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association. J Nucl Med. 2013;54(3):476\u201390. https:\/\/doi.org\/10.2967\/jnumed.113.120618.","journal-title":"J Nucl Med"},{"issue":"4","key":"879_CR33","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/j.jalz.2013.06.001","volume":"9","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging. Alzheimers Dement. 2013;9(4):e106\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2013.06.001.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"879_CR34","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2967\/jnumed.113.127068","volume":"54","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. J Nucl Med. 2013;54(7):1011\u20133. https:\/\/doi.org\/10.2967\/jnumed.113.127068.","journal-title":"J Nucl Med"},{"issue":"1","key":"879_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14338","volume":"21","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, et al. Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimers Dement. 2025;21(1):e14338. https:\/\/doi.org\/10.1002\/alz.14338.","journal-title":"Alzheimers Dement"},{"issue":"Suppl. 2","key":"879_CR36","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.2967\/jnumed.124.268756","volume":"66","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, et al. Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. J Nucl Med. 2025;66(Suppl. 2):S5-31. https:\/\/doi.org\/10.2967\/jnumed.124.268756.","journal-title":"J Nucl Med"},{"issue":"13","key":"879_CR37","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1021\/jm030026b","volume":"46","author":"CA Mathis","year":"2003","unstructured":"Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46(13):2740\u201354. https:\/\/doi.org\/10.1021\/jm030026b.","journal-title":"J Med Chem"},{"issue":"5","key":"879_CR38","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/0197-4580(95)00052-g","volume":"16","author":"H Levine 3rd","year":"1995","unstructured":"Levine H 3rd. Soluble multimeric Alzheimer beta(1\u201340) pre-amyloid complexes in dilute solution. Neurobiol Aging. 1995;16(5):755\u201364. https:\/\/doi.org\/10.1016\/0197-4580(95)00052-g.","journal-title":"Neurobiol Aging"},{"issue":"6","key":"879_CR39","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1053\/j.semnuclmed.2012.07.001","volume":"42","author":"CA Mathis","year":"2012","unstructured":"Mathis CA, Mason NS, Lopresti BJ, Klunk WE. Development of positron emission tomography beta-amyloid plaque imaging agents. Semin Nucl Med. 2012;42(6):423\u201332. https:\/\/doi.org\/10.1053\/j.semnuclmed.2012.07.001.","journal-title":"Semin Nucl Med"},{"issue":"6","key":"879_CR40","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1523\/JNEUROSCI.23-06-02086.2003","volume":"23","author":"WE Klunk","year":"2003","unstructured":"Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Shao L, et al. The binding of 2-(4\u2019-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci. 2003;23(6):2086\u201392. https:\/\/doi.org\/10.1523\/JNEUROSCI.23-06-02086.2003.","journal-title":"J Neurosci"},{"issue":"3","key":"879_CR41","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh compound-B. Ann Neurol. 2004;55(3):306\u201319. https:\/\/doi.org\/10.1002\/ana.20009.","journal-title":"Ann Neurol"},{"issue":"3","key":"879_CR42","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1001\/archneur.64.3.431","volume":"64","author":"BJ Bacskai","year":"2007","unstructured":"Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, et al. Molecular imaging with Pittsburgh compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64(3):431\u20134. https:\/\/doi.org\/10.1001\/archneur.64.3.431.","journal-title":"Arch Neurol"},{"issue":"Pt 6","key":"879_CR43","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/brain\/awn016","volume":"131","author":"MD Ikonomovic","year":"2008","unstructured":"Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer\u2019s disease. Brain. 2008;131(Pt 6):1630\u201345. https:\/\/doi.org\/10.1093\/brain\/awn016.","journal-title":"Brain"},{"issue":"3","key":"879_CR44","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00401-012-0943-2","volume":"123","author":"MD Ikonomovic","year":"2012","unstructured":"Ikonomovic MD, Abrahamson EE, Price JC, Hamilton RL, Mathis CA, Paljug WR, et al. Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathol. 2012;123(3):433\u201347. https:\/\/doi.org\/10.1007\/s00401-012-0943-2.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"879_CR45","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1212\/01.wnl.0000228230.26044.a4","volume":"67","author":"MA Mintun","year":"2006","unstructured":"Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446\u201352. https:\/\/doi.org\/10.1212\/01.wnl.0000228230.26044.a4.","journal-title":"Neurology"},{"issue":"1","key":"879_CR46","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/ana.21843","volume":"67","author":"JC Morris","year":"2010","unstructured":"Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122\u201331. https:\/\/doi.org\/10.1002\/ana.21843.","journal-title":"Ann Neurol"},{"issue":"10","key":"879_CR47","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1212\/WNL.0b013e3181d3e3e9","volume":"74","author":"SM Resnick","year":"2010","unstructured":"Resnick SM, Sojkova J, Zhou Y, An Y, Ye W, Holt DP, et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology. 2010;74(10):807\u201315. https:\/\/doi.org\/10.1212\/WNL.0b013e3181d3e3e9.","journal-title":"Neurology"},{"issue":"10","key":"879_CR48","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.neurobiolaging.2011.11.029","volume":"33","author":"M Storandt","year":"2012","unstructured":"Storandt M, Head D, Fagan AM, Holtzman DM, Morris JC. Toward a multifactorial model of Alzheimer disease. Neurobiol Aging. 2012;33(10):2262\u201371. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2011.11.029.","journal-title":"Neurobiol Aging"},{"issue":"6","key":"879_CR49","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.neuropsychologia.2008.02.008","volume":"46","author":"VL Villemagne","year":"2008","unstructured":"Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer\u2019s disease. Neuropsychologia. 2008;46(6):1688\u201397. https:\/\/doi.org\/10.1016\/j.neuropsychologia.2008.02.008.","journal-title":"Neuropsychologia"},{"issue":"1","key":"879_CR50","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ana.22248","volume":"69","author":"VL Villemagne","year":"2011","unstructured":"Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69(1):181\u201392. https:\/\/doi.org\/10.1002\/ana.22248.","journal-title":"Ann Neurol"},{"issue":"10","key":"879_CR51","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1001\/jamaneurol.2016.2642","volume":"73","author":"BA Gordon","year":"2016","unstructured":"Gordon BA, Blazey T, Su Y, Fagan AM, Holtzman DM, Morris JC, et al. Longitudinal beta-amyloid deposition and hippocampal volume in preclinical Alzheimer disease and suspected non-Alzheimer disease pathophysiology. JAMA Neurol. 2016;73(10):1192\u2013200. https:\/\/doi.org\/10.1001\/jamaneurol.2016.2642.","journal-title":"JAMA Neurol"},{"issue":"3","key":"879_CR52","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3233\/JAD-161074","volume":"57","author":"S Hatashita","year":"2017","unstructured":"Hatashita S, Wakebe D. Amyloid-beta deposition and long-term progression in mild cognitive impairment due to Alzheimer\u2019s disease defined with amyloid PET imaging. J Alzheimers Dis. 2017;57(3):765\u201373. https:\/\/doi.org\/10.3233\/JAD-161074.","journal-title":"J Alzheimers Dis"},{"issue":"Pt 4","key":"879_CR53","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1093\/brain\/awv007","volume":"138","author":"W Huijbers","year":"2015","unstructured":"Huijbers W, Mormino EC, Schultz AP, Wigman S, Ward AM, Larvie M, et al. Amyloid-beta deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain. 2015;138(Pt 4):1023\u201335. https:\/\/doi.org\/10.1093\/brain\/awv007.","journal-title":"Brain"},{"issue":"12","key":"879_CR54","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1212\/WNL.0b013e318212015e","volume":"76","author":"J Koivunen","year":"2011","unstructured":"Koivunen J, Scheinin N, Virta JR, Aalto S, Vahlberg T, Nagren K, et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology. 2011;76(12):1085\u201390. https:\/\/doi.org\/10.1212\/WNL.0b013e318212015e.","journal-title":"Neurology"},{"issue":"5","key":"879_CR55","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/ana.21598","volume":"65","author":"DA Wolk","year":"2009","unstructured":"Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009;65(5):557\u201368. https:\/\/doi.org\/10.1002\/ana.21598.","journal-title":"Ann Neurol"},{"issue":"3","key":"879_CR56","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"879_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010386.pub2","volume":"2014","author":"S Zhang","year":"2014","unstructured":"Zhang S, Smailagic N, Hyde C, Noel-Storr AH, Takwoingi Y, McShane R, et al. (11)C-PIB-PET for the early diagnosis of Alzheimer\u2019s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2014;2014(7):CD010386. https:\/\/doi.org\/10.1002\/14651858.CD010386.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"27","key":"879_CR58","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000150","volume":"93","author":"Y Ma","year":"2014","unstructured":"Ma Y, Zhang S, Li J, Zheng DM, Guo Y, Feng J, et al. Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. Medicine (Baltimore). 2014;93(27):e150. https:\/\/doi.org\/10.1097\/MD.0000000000000150.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"879_CR59","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/jnc.13887","volume":"140","author":"G Yamin","year":"2017","unstructured":"Yamin G, Teplow DB. Pittsburgh Compound-B (PiB) binds amyloid beta-protein protofibrils. J Neurochem. 2017;140(2):210\u20135. https:\/\/doi.org\/10.1111\/jnc.13887.","journal-title":"J Neurochem"},{"issue":"Pt 11","key":"879_CR60","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1093\/brain\/awl178","volume":"129","author":"H Engler","year":"2006","unstructured":"Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer\u2019s disease. Brain. 2006;129(Pt 11):2856\u201366. https:\/\/doi.org\/10.1093\/brain\/awl178.","journal-title":"Brain"},{"issue":"Pt 3","key":"879_CR61","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/brain\/awv404","volume":"139","author":"E Rodriguez-Vieitez","year":"2016","unstructured":"Rodriguez-Vieitez E, Saint-Aubert L, Carter SF, Almkvist O, Farid K, Scholl M, et al. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer\u2019s disease. Brain. 2016;139(Pt 3):922\u201336. https:\/\/doi.org\/10.1093\/brain\/awv404.","journal-title":"Brain"},{"issue":"3","key":"879_CR62","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1212\/WNL.0b013e31825fdf18","volume":"79","author":"M Scholl","year":"2012","unstructured":"Scholl M, Wall A, Thordardottir S, Ferreira D, Bogdanovic N, Langstrom B, et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology. 2012;79(3):229\u201336. https:\/\/doi.org\/10.1212\/WNL.0b013e31825fdf18.","journal-title":"Neurology"},{"issue":"1","key":"879_CR63","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/ana.23748","volume":"73","author":"TJ Esparza","year":"2013","unstructured":"Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, et al. Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol. 2013;73(1):104\u201319. https:\/\/doi.org\/10.1002\/ana.23748.","journal-title":"Ann Neurol"},{"issue":"6880","key":"879_CR64","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/416535a","volume":"416","author":"DM Walsh","year":"2002","unstructured":"Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416(6880):535\u20139. https:\/\/doi.org\/10.1038\/416535a.","journal-title":"Nature"},{"issue":"6","key":"879_CR65","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/1531-8249(199912)46:6<860::aid-ana8>3.0.co;2-m","volume":"46","author":"CA McLean","year":"1999","unstructured":"McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer\u2019s disease. Ann Neurol. 1999;46(6):860\u20136. https:\/\/doi.org\/10.1002\/1531-8249(199912)46:6%3c860::aid-ana8%3e3.0.co;2-m.","journal-title":"Ann Neurol"},{"issue":"11","key":"879_CR66","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s11604-019-00867-7","volume":"37","author":"H Matsuda","year":"2019","unstructured":"Matsuda H, Shigemoto Y, Sato N. Neuroimaging of Alzheimer\u2019s disease: focus on amyloid and tau PET. Jpn J Radiol. 2019;37(11):735\u201349. https:\/\/doi.org\/10.1007\/s11604-019-00867-7.","journal-title":"Jpn J Radiol"},{"issue":"8","key":"879_CR67","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.nucmedbio.2005.06.001","volume":"32","author":"W Zhang","year":"2005","unstructured":"Zhang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF. F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Nucl Med Biol. 2005;32(8):799\u2013809. https:\/\/doi.org\/10.1016\/j.nucmedbio.2005.06.001.","journal-title":"Nucl Med Biol"},{"key":"879_CR68","unstructured":"FDA approves 18F-florbetapir PET agent. J Nucl Med. 2012;53(6):15N."},{"issue":"10","key":"879_CR69","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMp1208061","volume":"367","author":"L Yang","year":"2012","unstructured":"Yang L, Rieves D, Ganley C. Brain amyloid imaging: FDA approval of florbetapir F18 injection. N Engl J Med. 2012;367(10):885\u20137. https:\/\/doi.org\/10.1056\/NEJMp1208061.","journal-title":"N Engl J Med"},{"key":"879_CR70","unstructured":"Eli Lilly and Company. FDA approves Amyvid\u2122 (Florbetapir F 18 Injection) for use in patients being evaluated for Alzheimer\u2019s disease and other causes of cognitive decline. Indianapolis (IN): Eli Lilly and Company\/PRNewswire; 2012. https:\/\/investor.lilly.com\/static-files\/4e34f099-0977-4e03-bd54-b7fa3b3c7373. Accessed 1 Sept 2026."},{"issue":"5 Suppl.","key":"879_CR71","doi-asserted-by":"publisher","first-page":"S395","DOI":"10.1016\/j.jalz.2013.09.007","volume":"10","author":"A Cortes-Blanco","year":"2014","unstructured":"Cortes-Blanco A, Prieto-Yerro C, Martinez-Lazaro R, Zamora J, Jim\u00e9nez-Huete A, Haberkamp M, et al. Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval. Alzheimers Dement. 2014;10(5 Suppl.):S395\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2013.09.007.","journal-title":"Alzheimers Dement"},{"key":"879_CR72","unstructured":"European Medicines Agency. Amyvid (florbetapir 18F): EPAR summary for the public. London: European Medicines Agency (EMA); 2013. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/amyvid-epar-summary-public_en.pdf. Accessed 1 Sept 2026."},{"issue":"11","key":"879_CR73","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.2967\/jnumed.109.065284","volume":"50","author":"SR Choi","year":"2009","unstructured":"Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med. 2009;50(11):1887\u201394. https:\/\/doi.org\/10.2967\/jnumed.109.065284.","journal-title":"J Nucl Med"},{"issue":"4","key":"879_CR74","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.nucmedbio.2011.10.007","volume":"39","author":"MM Svedberg","year":"2012","unstructured":"Svedberg MM, Rahman O, Hall H. Preclinical studies of potential amyloid binding PET\/SPECT ligands in Alzheimer\u2019s disease. Nucl Med Biol. 2012;39(4):484\u2013501. https:\/\/doi.org\/10.1016\/j.nucmedbio.2011.10.007.","journal-title":"Nucl Med Biol"},{"issue":"9","key":"879_CR75","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1136\/jnnp-2012-302548","volume":"83","author":"DA Wolk","year":"2012","unstructured":"Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE. Amyloid imaging in Alzheimer\u2019s disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry. 2012;83(9):923\u20136. https:\/\/doi.org\/10.1136\/jnnp-2012-302548.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"879_CR76","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2967\/jnumed.112.109009","volume":"54","author":"SM Landau","year":"2013","unstructured":"Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013;54(1):70\u20137. https:\/\/doi.org\/10.2967\/jnumed.112.109009.","journal-title":"J Nucl Med"},{"issue":"1","key":"879_CR77","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/NEN.0000000000000028","volume":"73","author":"BN Dugger","year":"2014","unstructured":"Dugger BN, Clark CM, Serrano G, Mariner M, Bedell BJ, Coleman RE, et al. Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. J Neuropathol Exp Neurol. 2014;73(1):72\u201380. https:\/\/doi.org\/10.1097\/NEN.0000000000000028.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"9","key":"879_CR78","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/mp.2014.9","volume":"19","author":"PM Doraiswamy","year":"2014","unstructured":"Doraiswamy PM, Sperling RA, Johnson K, Reiman EM, Wong TZ, Sabbagh MN, et al. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry. 2014;19(9):1044\u201351. https:\/\/doi.org\/10.1038\/mp.2014.9.","journal-title":"Mol Psychiatry"},{"issue":"20","key":"879_CR79","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1212\/WNL.0000000000004643","volume":"89","author":"MJ Grothe","year":"2017","unstructured":"Grothe MJ, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel SJ, et al. In vivo staging of regional amyloid deposition. Neurology. 2017;89(20):2031\u20138. https:\/\/doi.org\/10.1212\/WNL.0000000000004643.","journal-title":"Neurology"},{"issue":"1","key":"879_CR80","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3233\/JAD-190818","volume":"74","author":"L Beyer","year":"2020","unstructured":"Beyer L, Brendel M, Scheiwein F, Sauerbeck J, Hosakawa C, Alberts I, et al. Improved risk stratification for progression from mild cognitive impairment to Alzheimer\u2019s disease with a multi-analytical evaluation of amyloid-beta positron emission tomography. J Alzheimers Dis. 2020;74(1):101\u201312. https:\/\/doi.org\/10.3233\/JAD-190818.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"879_CR81","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1474-4422(18)30029-2","volume":"17","author":"B Dubois","year":"2018","unstructured":"Dubois B, Epelbaum S, Nyasse F, Bakardjian H, Gagliardi G, Uspenskaya O, et al. Cognitive and neuroimaging features and brain beta-amyloidosis in individuals at risk of Alzheimer\u2019s disease (INSIGHT-preAD): a longitudinal observational study. Lancet Neurol. 2018;17(4):335\u201346. https:\/\/doi.org\/10.1016\/S1474-4422(18)30029-2.","journal-title":"Lancet Neurol"},{"key":"879_CR82","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.neurobiolaging.2020.03.011","volume":"93","author":"SJ Teipel","year":"2020","unstructured":"Teipel SJ, Dyrba M, Chiesa PA, Sakr F, Jelistratova I, Lista S, et al. In vivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer\u2019s disease. Neurobiol Aging. 2020;93:98\u2013108. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2020.03.011.","journal-title":"Neurobiol Aging"},{"issue":"7","key":"879_CR83","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s40263-015-0258-7","volume":"29","author":"YY Syed","year":"2015","unstructured":"Syed YY, Deeks E. [(18)F]Florbetaben: a review in beta-amyloid PET imaging in cognitive impairment. CNS Drugs. 2015;29(7):605\u201313. https:\/\/doi.org\/10.1007\/s40263-015-0258-7.","journal-title":"CNS Drugs"},{"key":"879_CR84","unstructured":"Piramal Life Sciences. FDA approves Piramal Imaging\u2019s Neuraceq\u2122 (florbetaben F18 injection) for PET imaging of beta-amyloid neuritic plaques in the brain. Berlin\/Boston: Piramal Imaging\/Piramal Enterprises, Ltd.; 2014. https:\/\/www.wmis.org\/wp-content\/uploads\/2014\/03\/FDA-Approval-Press-Release.pdf. Accessed 1 Sept 2026."},{"key":"879_CR85","unstructured":"European Medicines Agency. Neuraceq (florbetaben 18F): EPAR summary for the public. London: European Medicines Agency (EMA); 2016. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/neuraceq-epar-summary-public_en.pdf. Accessed 1 Sept 2026."},{"issue":"12","key":"879_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/ph17121648","volume":"17","author":"A Jovalekic","year":"2024","unstructured":"Jovalekic A, Bullich S, Roe-Vellve N, Kolinger GD, Howard LR, Elsholz F, et al. Experiences from clinical research and routine use of florbetaben amyloid PET: a decade of post-authorization insights. Pharmaceuticals (Basel). 2024;17(12):1648. https:\/\/doi.org\/10.3390\/ph17121648.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"879_CR87","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.nucmedbio.2012.03.001","volume":"39","author":"MT Fodero-Tavoletti","year":"2012","unstructured":"Fodero-Tavoletti MT, Brockschnieder D, Villemagne VL, Martin L, Connor AR, Thiele A, et al. In vitro characterization of [18F]-florbetaben, an Abeta imaging radiotracer. Nucl Med Biol. 2012;39(7):1042\u20138. https:\/\/doi.org\/10.1016\/j.nucmedbio.2012.03.001.","journal-title":"Nucl Med Biol"},{"issue":"1","key":"879_CR88","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40336-015-0102-6","volume":"3","author":"O Sabri","year":"2015","unstructured":"Sabri O, Seibyl J, Rowe C, Barthel H. Beta-amyloid imaging with florbetaben. Clin Transl Imaging. 2015;3(1):13\u201326. https:\/\/doi.org\/10.1007\/s40336-015-0102-6.","journal-title":"Clin Transl Imaging"},{"issue":"2","key":"879_CR89","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","volume":"7","author":"CC Rowe","year":"2008","unstructured":"Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O\u2019Keefe G, et al. Imaging of amyloid beta in Alzheimer\u2019s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7(2):129\u201335. https:\/\/doi.org\/10.1016\/S1474-4422(08)70001-2.","journal-title":"Lancet Neurol"},{"issue":"8","key":"879_CR90","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.2967\/jnumed.111.089730","volume":"52","author":"VL Villemagne","year":"2011","unstructured":"Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52(8):1210\u20137. https:\/\/doi.org\/10.2967\/jnumed.111.089730.","journal-title":"J Nucl Med"},{"issue":"9","key":"879_CR91","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1007\/s00259-011-1821-1","volume":"38","author":"H Barthel","year":"2011","unstructured":"Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, et al. Individualized quantification of brain beta-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer\u2019s disease and healthy controls. Eur J Nucl Med Mol Imaging. 2011;38(9):1702\u201314. https:\/\/doi.org\/10.1007\/s00259-011-1821-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"879_CR92","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","volume":"10","author":"H Barthel","year":"2011","unstructured":"Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer\u2019s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424\u201335. https:\/\/doi.org\/10.1016\/S1474-4422(11)70077-1.","journal-title":"Lancet Neurol"},{"issue":"8","key":"879_CR93","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","volume":"11","author":"O Sabri","year":"2015","unstructured":"Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: phase 3 study. Alzheimers Dement. 2015;11(8):964\u201374. https:\/\/doi.org\/10.1016\/j.jalz.2015.02.004.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"879_CR94","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3233\/JAD-2012-121315","volume":"33","author":"A Bahar-Fuchs","year":"2013","unstructured":"Bahar-Fuchs A, Villemagne V, Ong K, Chetelat G, Lamb F, Reininger CB, et al. Prediction of amyloid-beta pathology in amnestic mild cognitive impairment with neuropsychological tests. J Alzheimers Dis. 2013;33(2):451\u201362. https:\/\/doi.org\/10.3233\/JAD-2012-121315.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"879_CR95","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/alzrt158","volume":"5","author":"K Ong","year":"2013","unstructured":"Ong K, Villemagne VL, Bahar-Fuchs A, Lamb F, Chetelat G, Raniga P, et al. (18)F-florbetaben Abeta imaging in mild cognitive impairment. Alzheimers Res Ther. 2013;5(1):4. https:\/\/doi.org\/10.1186\/alzrt158.","journal-title":"Alzheimers Res Ther."},{"issue":"4","key":"879_CR96","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1136\/jnnp-2014-308094","volume":"86","author":"KT Ong","year":"2015","unstructured":"Ong KT, Villemagne VL, Bahar-Fuchs A, Lamb F, Langdon N, Catafau AM, et al. Abeta imaging with 18F-florbetaben in prodromal Alzheimer\u2019s disease: a prospective outcome study. J Neurol Neurosurg Psychiatry. 2015;86(4):431\u20136. https:\/\/doi.org\/10.1136\/jnnp-2014-308094.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"879_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2018.00158","volume":"10","author":"F Segovia","year":"2018","unstructured":"Segovia F, Sanchez-Vano R, Gorriz JM, Ramirez J, Sopena-Novales P, Testart Dardel N, et al. Using CT data to improve the quantitative analysis of (18)F-FBB PET neuroimages. Front Aging Neurosci. 2018;10:158. https:\/\/doi.org\/10.3389\/fnagi.2018.00158.","journal-title":"Front Aging Neurosci"},{"issue":"9","key":"879_CR98","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1007\/s00259-016-3353-1","volume":"43","author":"S Tiepolt","year":"2016","unstructured":"Tiepolt S, Hesse S, Patt M, Luthardt J, Schroeter ML, Hoffmann KT, et al. Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2016;43(9):1700\u20139. https:\/\/doi.org\/10.1007\/s00259-016-3353-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"879_CR99","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3233\/JAD-180522","volume":"66","author":"L Florek","year":"2018","unstructured":"Florek L, Tiepolt S, Schroeter ML, Berrouschot J, Saur D, Hesse S, et al. Dual time-point [18F]Florbetaben PET delivers dual biomarker information in mild cognitive impairment and Alzheimer\u2019s disease. J Alzheimers Dis. 2018;66(3):1105\u201316. https:\/\/doi.org\/10.3233\/JAD-180522.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"879_CR100","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s11307-018-1167-1","volume":"20","author":"A Chiaravalloti","year":"2018","unstructured":"Chiaravalloti A, Castellano AE, Ricci M, Barbagallo G, Sannino P, Ursini F, et al. Coupled imaging with [(18)F]FBB and [(18)F]FDG in AD subjects show a selective association between amyloid burden and cortical dysfunction in the brain. Mol Imaging Biol. 2018;20(4):659\u201366. https:\/\/doi.org\/10.1007\/s11307-018-1167-1.","journal-title":"Mol Imaging Biol"},{"issue":"1","key":"879_CR101","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1097\/RLU.0000000000002768","volume":"45","author":"SH Son","year":"2020","unstructured":"Son SH, Kang K, Ko PW, Lee HW, Lee SW, Ahn BC, et al. Early-phase 18F-Florbetaben PET as an alternative modality for 18F-FDG PET. Clin Nucl Med. 2020;45(1):e8-14. https:\/\/doi.org\/10.1097\/RLU.0000000000002768.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"879_CR102","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00259-015-3208-1","volume":"43","author":"K Heurling","year":"2016","unstructured":"Heurling K, Leuzy A, Zimmer ER, Lubberink M, Nordberg A. Imaging beta-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis. Eur J Nucl Med Mol Imaging. 2016;43(2):362\u201373. https:\/\/doi.org\/10.1007\/s00259-015-3208-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"879_CR103","unstructured":"GE HealthCare. FDA approval of viazmyl (flutemetamol F18 injection) for detection of beta amyloid. Princeton, NJ: GE Healthcare; 2013. https:\/\/www.gehealthcare.com\/en-sg\/news-center\/fda-approves-vizamyl?srsltid=AfmBOopA83fw9j2ztGPFAHktYS7UyeGSzCynMLkxIaw5cQ-k7MEcojOd. https:\/\/www.gehealthcare.com\/en-sg\/-\/jssmedia\/widen\/2018\/01\/25\/0204\/gehealthcarecom\/migrated\/2018\/04\/24\/0243\/bal-news-center-fda-approves-vizamyl-gehc-press-release_fda-approves-vizamyl_20131028_docx.docx?rev=-1. Accessed 1 Sept 2026."},{"key":"879_CR104","unstructured":"GE HealthCare. GE Healthcare announces FDA approval of Vizamyl\u2122 (flutemetamol F18 injection) for detection of beta amyloid: new PET imaging agent provides brain scans in color. Princeton (NJ). 2013. https:\/\/www.gehealthcare.com\/en-sg\/-\/jssmedia\/widen\/2018\/01\/25\/0204\/gehealthcarecom\/migrated\/2018\/04\/24\/0243\/bal-news-center-fda-approves-vizamyl-gehc-press-release_fda-approves-vizamyl_20131028_docx.docx?rev=-1. Accessed 1 Sept 2026."},{"key":"879_CR105","unstructured":"European Medicines Agency. Vizamyl flutemetamol (18F): EPAR summary for the public. EMA\/481900\/2016. EMEA\/H\/C\/002557. 2016. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/vizamyl-epar-summary-public_en.pdf. Accessed 1 Sept 2026."},{"key":"879_CR106","unstructured":"US Food and Drug Administration. Vizamyl\u2122 (flutemetamol F 18 injection), for intravenous use. Full prescribing information. Arlington Heights (IL): GE HealthCare, Medi-Physics, Inc.; 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/203137s024lbl.pdf. Accessed 1 Sept 2026."},{"key":"879_CR107","doi-asserted-by":"publisher","first-page":"T113","DOI":"10.1016\/j.neuroimage.2008.04.082","volume":"41","author":"CA Mathis","year":"2008","unstructured":"Mathis CA, Ikonomovic MD, Debnath ML, Hamilton RL, DeKosky ST, Klunk WE. Comparison of the binding of 3\u2032-F-PiB and PiB in human brain homogenates. Neuroimage. 2008;41:T113\u20134. https:\/\/doi.org\/10.1016\/j.neuroimage.2008.04.082.","journal-title":"Neuroimage"},{"issue":"8","key":"879_CR108","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2967\/jnumed.109.063305","volume":"50","author":"N Nelissen","year":"2009","unstructured":"Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009;50(8):1251\u20139. https:\/\/doi.org\/10.2967\/jnumed.109.063305.","journal-title":"J Nucl Med"},{"issue":"3","key":"879_CR109","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ana.22068","volume":"68","author":"R Vandenberghe","year":"2010","unstructured":"Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68(3):319\u201329. https:\/\/doi.org\/10.1002\/ana.22068.","journal-title":"Ann Neurol"},{"issue":"3","key":"879_CR110","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","volume":"72","author":"C Curtis","year":"2015","unstructured":"Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72(3):287\u201394. https:\/\/doi.org\/10.1001\/jamaneurol.2014.4144.","journal-title":"JAMA Neurol"},{"issue":"8","key":"879_CR111","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jalz.2015.05.018","volume":"11","author":"DR Thal","year":"2015","unstructured":"Thal DR, Beach TG, Zanette M, Heurling K, Chakrabarty A, Ismail A, et al. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer\u2019s disease: specific detection of advanced phases of amyloid-beta pathology. Alzheimers Dement. 2015;11(8):975\u201385. https:\/\/doi.org\/10.1016\/j.jalz.2015.05.018.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"879_CR112","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00401-018-1897-9","volume":"136","author":"DR Thal","year":"2018","unstructured":"Thal DR, Beach TG, Zanette M, Lilja J, Heurling K, Chakrabarty A, et al. Estimation of amyloid distribution by [(18)F]flutemetamol PET predicts the neuropathological phase of amyloid beta-protein deposition. Acta Neuropathol. 2018;136(4):557\u201367. https:\/\/doi.org\/10.1007\/s00401-018-1897-9.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"879_CR113","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13195-019-0577-x","volume":"12","author":"SE Kim","year":"2020","unstructured":"Kim SE, Lee B, Park S, Cho SH, Kim SJ, Kim Y, et al. Clinical significance of focal ss-amyloid deposition measured by (18)F-flutemetamol PET. Alzheimers Res Ther. 2020;12(1):6. https:\/\/doi.org\/10.1186\/s13195-019-0577-x.","journal-title":"Alzheimers Res Ther."},{"issue":"2","key":"879_CR114","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00259-013-2564-y","volume":"41","author":"S Hatashita","year":"2014","unstructured":"Hatashita S, Yamasaki H, Suzuki Y, Tanaka K, Wakebe D, Hayakawa H. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2014;41(2):290\u2013300. https:\/\/doi.org\/10.1007\/s00259-013-2564-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"879_CR115","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s00259-015-3156-9","volume":"43","author":"K Adamczuk","year":"2016","unstructured":"Adamczuk K, Schaeverbeke J, Nelissen N, Neyens V, Vandenbulcke M, Goffin K, et al. Amyloid imaging in cognitively normal older adults: comparison between (18)F-flutemetamol and (11)C-Pittsburgh compound B. Eur J Nucl Med Mol Imaging. 2016;43(1):142\u201351. https:\/\/doi.org\/10.1007\/s00259-015-3156-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"879_CR116","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3389\/fnagi.2019.00251","volume":"11","author":"S Hatashita","year":"2019","unstructured":"Hatashita S, Wakebe D, Kikuchi Y, Ichijo A. Longitudinal assessment of amyloid-beta deposition by [18F]-flutemetamol PET imaging compared with [11C]-PIB across the spectrum of Alzheimer\u2019s disease. Front Aging Neurosci. 2019;11:251. https:\/\/doi.org\/10.3389\/fnagi.2019.00251.","journal-title":"Front Aging Neurosci."},{"issue":"2","key":"879_CR117","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s00259-015-3228-x","volume":"43","author":"E Morris","year":"2016","unstructured":"Morris E, Chalkidou A, Hammers A, Peacock J, Summers J, Keevil S. Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2016;43(2):374\u201385. https:\/\/doi.org\/10.1007\/s00259-015-3228-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"879_CR118","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.dadm.2014.11.004","volume":"1","author":"JM Yeo","year":"2015","unstructured":"Yeo JM, Waddell B, Khan Z, Pal S. A systematic review and meta-analysis of (18)F-labeled amyloid imaging in Alzheimer\u2019s disease. Alzheimers Dement (Amst). 2015;1(1):5\u201313. https:\/\/doi.org\/10.1016\/j.dadm.2014.11.004.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"5","key":"879_CR119","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70304","volume":"21","author":"M Abu Raya","year":"2025","unstructured":"Abu Raya M, Zeltzer E, Blazhenets G, Schonhaut DR, Allen IE, Carrillo MC, et al. Sex differences in amyloid PET in a large, real-world sample from the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) study. Alzheimers Dement. 2025;21(5):e70304. https:\/\/doi.org\/10.1002\/alz.70304.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"879_CR120","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1001\/jamaneurol.2022.3157","volume":"79","author":"CH Wilkins","year":"2022","unstructured":"Wilkins CH, Windon CC, Dilworth-Anderson P, Romanoff J, Gatsonis C, Hanna L, et al. Racial and ethnic differences in amyloid PET positivity in individuals with mild cognitive impairment or dementia: a secondary analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) cohort study. JAMA Neurol. 2022;79(11):1139\u201347. https:\/\/doi.org\/10.1001\/jamaneurol.2022.3157.","journal-title":"JAMA Neurol"},{"issue":"6","key":"879_CR121","doi-asserted-by":"publisher","first-page":"880","DOI":"10.2967\/jnumed.112.114785","volume":"54","author":"CC Rowe","year":"2013","unstructured":"Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, et al. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia. J Nucl Med. 2013;54(6):880\u20136. https:\/\/doi.org\/10.2967\/jnumed.112.114785.","journal-title":"J Nucl Med"},{"key":"879_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2025.112216","volume":"226","author":"P Kumar","year":"2025","unstructured":"Kumar P, Mangalore S, Joshi RK, Murthy V, Kumar A, Sitani K, et al. Production of [(18)F]NAV4694 on an FX2N synthesis module for imaging amyloid plaques. Appl Radiat Isot. 2025;226:112216. https:\/\/doi.org\/10.1016\/j.apradiso.2025.112216.","journal-title":"Appl Radiat Isot"},{"key":"879_CR123","doi-asserted-by":"publisher","unstructured":"Bettcher B, McLachlan M, Zammit M, McVea A, DiFilippo AH, Murali D, et al. Longitudinal amyloid burden with combined [(11)C]PiB and [(18)F]NAV4694 PET scans. Imaging Neurosci (Camb). 2026;4:IMAG.a.1148. https:\/\/doi.org\/10.1162\/IMAG.a.1148.","DOI":"10.1162\/IMAG.a.1148"},{"issue":"4","key":"879_CR124","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1177\/13872877241313063","volume":"103","author":"A Gillman","year":"2025","unstructured":"Gillman A, Bourgeat P, Cox T, Villemagne VL, Fripp J, Huang K, et al. Digital detector PET\/CT increases Centiloid measures of amyloid in Alzheimer\u2019s disease: a head-to-head comparison of cameras. J Alzheimers Dis. 2025;103(4):1257\u201368. https:\/\/doi.org\/10.1177\/13872877241313063.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"879_CR125","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s13277-012-0316-4","volume":"33","author":"GA van Dongen","year":"2012","unstructured":"van Dongen GA, Poot AJ, Vugts DJ. PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumour Biol. 2012;33(3):607\u201315. https:\/\/doi.org\/10.1007\/s13277-012-0316-4.","journal-title":"Tumour Biol"},{"issue":"8","key":"879_CR126","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00259-009-1096-y","volume":"36","author":"BM Tijink","year":"2009","unstructured":"Tijink BM, Perk LR, Budde M, Stigter-van Walsum M, Visser GW, Kloet RW, et al. (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging. 2009;36(8):1235\u201344. https:\/\/doi.org\/10.1007\/s00259-009-1096-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"879_CR127","first-page":"1271","volume":"44","author":"I Verel","year":"2003","unstructured":"Verel I, Visser GW, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GA. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44(8):1271\u201381.","journal-title":"J Nucl Med"},{"key":"879_CR128","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.neuroimage.2017.01.004","volume":"148","author":"S Syvanen","year":"2017","unstructured":"Syvanen S, Fang XT, Hultqvist G, Meier SR, Lannfelt L, Sehlin D. A bispecific tribody PET radioligand for visualization of amyloid-beta protofibrils: a new concept for neuroimaging. Neuroimage. 2017;148:55\u201363. https:\/\/doi.org\/10.1016\/j.neuroimage.2017.01.004.","journal-title":"Neuroimage"},{"key":"879_CR129","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.neuroimage.2018.10.011","volume":"184","author":"XT Fang","year":"2019","unstructured":"Fang XT, Hultqvist G, Meier SR, Antoni G, Sehlin D, Syvanen S. High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain. Neuroimage. 2019;184:881\u20138. https:\/\/doi.org\/10.1016\/j.neuroimage.2018.10.011.","journal-title":"Neuroimage"},{"key":"879_CR130","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/978-3-642-20910-9_8","volume-title":"Bispecific antibodies","author":"N Mertens","year":"2011","unstructured":"Mertens N. Tribodies: Fab\u2013scFv fusion proteins as a platform to create multifunctional pharmaceuticals. In: Kontermann RE, editor. Bispecific antibodies. Berlin: Springer; 2011. p. 135\u201349."},{"issue":"4","key":"879_CR131","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.3390\/molecules15042686","volume":"15","author":"L Koehler","year":"2010","unstructured":"Koehler L, Gagnon K, McQuarrie S, Wuest F. Iodine-124: a promising positron emitter for organic PET chemistry. Molecules. 2010;15(4):2686\u2013718. https:\/\/doi.org\/10.3390\/molecules15042686.","journal-title":"Molecules"},{"issue":"4","key":"879_CR132","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1039\/d4md00866a","volume":"16","author":"AC Kelleher","year":"2025","unstructured":"Kelleher AC, Tan C, Chan S, Khastgir R, Hu H, Youss Z, et al. Feasibility of F-18 radiolabeled brain-penetrable bi-specific antibody radioligands for in vivo PET imaging of tauopathy. RSC Med Chem. 2025;16(4):1808\u201317. https:\/\/doi.org\/10.1039\/d4md00866a.","journal-title":"RSC Med Chem"},{"key":"879_CR133","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41582-025-01126-2","volume":"21","author":"M Higuchi","year":"2025","unstructured":"Higuchi M, Tagai K, Takahata K, Endo H. Advances in PET imaging of protein aggregates associated with neurodegenerative disease. Nat Rev Neurol. 2025;21:506\u201322. https:\/\/doi.org\/10.1038\/s41582-025-01126-2.","journal-title":"Nat Rev Neurol"},{"key":"879_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106421","volume":"184","author":"A Willuweit","year":"2023","unstructured":"Willuweit A, Humpert S, Sch\u00f6neck M, Endepols H, Burda N, Gremer L, et al. Evaluation of the 18F-labeled analog of the therapeutic all-D-enantiomeric peptide RD2 for amyloid \u03b2 imaging. Eur J Pharm Sci. 2023;184:106421. https:\/\/doi.org\/10.1016\/j.ejps.2023.106421.","journal-title":"Eur J Pharm Sci"},{"key":"879_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2025.103765","volume":"46","author":"L Iaccarino","year":"2025","unstructured":"Iaccarino L, Burnham SC, Tunali I, Wang J, Navitsky M, Arora AK, et al. A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research. Neuroimage Clin. 2025;46:103765. https:\/\/doi.org\/10.1016\/j.nicl.2025.103765.","journal-title":"Neuroimage Clin."},{"issue":"7","key":"879_CR136","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3174\/ajnr.A4433","volume":"36","author":"S Minoshima","year":"2015","unstructured":"Minoshima S. Establishing amyloid PET imaging biomarkers: ongoing efforts. Am J Neuroradiol. 2015;36(7):1245\u20136. https:\/\/doi.org\/10.3174\/ajnr.A4433.","journal-title":"Am J Neuroradiol"},{"issue":"9","key":"879_CR137","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jamaneurol.2025.2218","volume":"82","author":"E Zeltzer","year":"2025","unstructured":"Zeltzer E, Schonhaut DR, Mundada NS, Blazhenets G, Soleimani-Meigooni DN, Cho H, et al. Concordance between amyloid-PET quantification and real-world visual reads. JAMA Neurol. 2025;82(9):952\u201362. https:\/\/doi.org\/10.1001\/jamaneurol.2025.2218.","journal-title":"JAMA Neurol"},{"issue":"1","key":"879_CR138","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2967\/jnumed.124.268119","volume":"66","author":"LE Collij","year":"2025","unstructured":"Collij LE, Bischof GN, Altomare D, Bader I, Battle M, Vallez Garcia D, et al. Quantification supports amyloid PET visual assessment of challenging cases: results from the AMYPAD diagnostic and patient management study. J Nucl Med. 2025;66(1):110\u20136. https:\/\/doi.org\/10.2967\/jnumed.124.268119.","journal-title":"J Nucl Med"},{"issue":"12","key":"879_CR139","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/alz.14336","volume":"20","author":"LE Collij","year":"2024","unstructured":"Collij LE, Bollack A, La Joie R, Shekari M, Bullich S, Roe-Vellve N, et al. Centiloid recommendations for clinical context-of-use from the AMYPAD consortium. Alzheimers Dement. 2024;20(12):903\u201348. https:\/\/doi.org\/10.1002\/alz.14336.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"879_CR140","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2174\/1568026611313080004","volume":"13","author":"F Zeng","year":"2013","unstructured":"Zeng F, Goodman MM. Fluorine-18 radiolabeled heterocycles as PET tracers for imaging beta-amyloid plaques in Alzheimer\u2019s disease. Curr Top Med Chem. 2013;13(8):909\u201319. https:\/\/doi.org\/10.2174\/1568026611313080004.","journal-title":"Curr Top Med Chem"},{"issue":"10","key":"879_CR141","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","volume":"49","author":"HG Pemberton","year":"2022","unstructured":"Pemberton HG, Collij LE, Heeman F, Bollack A, Shekari M, Salvado G, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging. 2022;49(10):3508\u201328. https:\/\/doi.org\/10.1007\/s00259-022-05784-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"879_CR142","doi-asserted-by":"publisher","unstructured":"Chiao P, Bedell BJ, Avants B, Zijdenbos AP, Grand\u2019Maison M, O\u2019Neill P, et al. Impact of reference and target region selection on amyloid PET SUV ratios in the phase 1b PRIME study of aducanumab. J Nucl Med. 2019;60(1):100\u20136. https:\/\/doi.org\/10.2967\/jnumed.118.209130.","DOI":"10.2967\/jnumed.118.209130"},{"key":"879_CR143","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.neuroimage.2013.01.015","volume":"71","author":"AD Cohen","year":"2013","unstructured":"Cohen AD, Mowrey W, Weissfeld LA, Aizenstein HJ, McDade E, Mountz JM, et al. Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. Neuroimage. 2013;71:207\u201315. https:\/\/doi.org\/10.1016\/j.neuroimage.2013.01.015.","journal-title":"Neuroimage"},{"issue":"5","key":"879_CR144","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2967\/jnumed.123.266188","volume":"65","author":"GP Ruwanpathirana","year":"2024","unstructured":"Ruwanpathirana GP, Williams RC, Masters CL, Rowe CC, Johnston LA, Davey CE. Impact of PET reconstruction on amyloid-beta quantitation in cross-sectional and longitudinal analyses. J Nucl Med. 2024;65(5):781\u20137. https:\/\/doi.org\/10.2967\/jnumed.123.266188.","journal-title":"J Nucl Med"},{"issue":"4","key":"879_CR145","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1053\/j.semnuclmed.2025.03.004","volume":"55","author":"L Filippi","year":"2025","unstructured":"Filippi L, Schillaci O. Global experience in brain amyloid imaging. Semin Nucl Med. 2025;55(4):538\u201347. https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.03.004.","journal-title":"Semin Nucl Med"},{"issue":"S8","key":"879_CR146","doi-asserted-by":"publisher","DOI":"10.1002\/alz70862_110011","volume":"21","author":"G Blazhenets","year":"2025","unstructured":"Blazhenets G, Snyder HM, Apostolova LG, Asken BM, Bejanin A, Bombois S, et al. Every Centiloid, from everywhere, all at once. Alzheimers Dement. 2025;21(S8):e110011. https:\/\/doi.org\/10.1002\/alz70862_110011.","journal-title":"Alzheimers Dement"},{"key":"879_CR147","doi-asserted-by":"publisher","first-page":"1168470","DOI":"10.3389\/fmed.2023.1168470","volume":"10","author":"DE Peretti","year":"2023","unstructured":"Peretti DE, Ribaldi F, Scheffler M, Mu L, Treyer V, Gietl AF, et al. ATN profile classification across two independent prospective cohorts. Front Med (Lausanne). 2023;10:1168470. https:\/\/doi.org\/10.3389\/fmed.2023.1168470.","journal-title":"Front Med (Lausanne)."},{"issue":"Suppl. 2","key":"879_CR148","volume":"21","author":"R Fahmi","year":"2025","unstructured":"Fahmi R, Bollack A, Battle MR, Farrar G, Spottiswoode B. Robustness of the Centiloid scale to target and reference regions calculated with a commercial software using [18F]flutemetamol PET images. Alzheimers Dement. 2025;21(Suppl. 2):e107393.21.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"879_CR149","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-018-0456-7","volume":"8","author":"MR Battle","year":"2018","unstructured":"Battle MR, Pillay LC, Lowe VJ, Knopman D, Kemp B, Rowe CC, et al. Centiloid scaling for quantification of brain amyloid with [(18)F]flutemetamol using multiple processing methods. EJNMMI Res. 2018;8(1):107. https:\/\/doi.org\/10.1186\/s13550-018-0456-7.","journal-title":"EJNMMI Res"},{"issue":"12","key":"879_CR150","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.2967\/jnumed.125.270607","volume":"66","author":"J Zhang","year":"2025","unstructured":"Zhang J, Soleimani-Meigooni DN, Koeppe R, Ackley S, Schonhaut DR, Lin ZE, et al. Exploring Centiloid robustness: impact of sample size and image resolution on Centiloid conversion accuracy. J Nucl Med. 2025;66(12):1976\u201384. https:\/\/doi.org\/10.2967\/jnumed.125.270607.","journal-title":"J Nucl Med"},{"issue":"8","key":"879_CR151","doi-asserted-by":"publisher","first-page":"5102","DOI":"10.1002\/alz.13883","volume":"20","author":"M Shekari","year":"2024","unstructured":"Shekari M, Vallez Garcia D, Collij LE, Altomare D, Heeman F, Pemberton H, et al. Stress testing the Centiloid: precision and variability of PET quantification of amyloid pathology. Alzheimers Dement. 2024;20(8):5102\u201313. https:\/\/doi.org\/10.1002\/alz.13883.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"879_CR152","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2967\/jnumed.124.268339","volume":"67","author":"K Chiotis","year":"2026","unstructured":"Chiotis K, Wang Y, La Joie R, Rabinovici GD. The role of amyloid-beta and tau PET in the new era of Alzheimer disease therapies. J Nucl Med. 2026;67(2):175\u201385. https:\/\/doi.org\/10.2967\/jnumed.124.268339.","journal-title":"J Nucl Med"},{"issue":"12","key":"879_CR153","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00259-017-3749-6","volume":"44","author":"CC Rowe","year":"2017","unstructured":"Rowe CC, Dore V, Jones G, Baxendale D, Mulligan RS, Bullich S, et al. (18)F-Florbetaben PET beta-amyloid binding expressed in Centiloids. Eur J Nucl Med Mol Imaging. 2017;44(12):2053\u20139. https:\/\/doi.org\/10.1007\/s00259-017-3749-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"879_CR154","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239.","journal-title":"JAMA"},{"issue":"1","key":"879_CR155","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"issue":"11","key":"879_CR156","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146(11):4414\u201324. https:\/\/doi.org\/10.1093\/brain\/awad188.","journal-title":"Brain"},{"issue":"4","key":"879_CR157","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1002\/alz.13735","volume":"20","author":"G Wang","year":"2024","unstructured":"Wang G, Li Y, Xiong C, Benzinger TLS, Gordon BA, Hassenstab J, et al. Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer\u2019s disease. Alzheimers Dement. 2024;20(4):2698\u2013706. https:\/\/doi.org\/10.1002\/alz.13735.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"879_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100150","volume":"12","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Selkoe DJ, Schindler SE, Aisen P, Apostolova LG, Atri A, et al. Donanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2025;12(5):100150. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100150.","journal-title":"J Prev Alzheimers Dis"},{"issue":"3","key":"879_CR159","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00259-022-05999-z","volume":"50","author":"J Wang","year":"2023","unstructured":"Wang J, Jin C, Zhou J, Zhou R, Tian M, Lee HJ, et al. PET molecular imaging for pathophysiological visualization in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2023;50(3):765\u201383. https:\/\/doi.org\/10.1007\/s00259-022-05999-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"879_CR160","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209419","volume":"103","author":"SE Mastenbroek","year":"2024","unstructured":"Mastenbroek SE, Sala A, Vallez Garcia D, Shekari M, Salvado G, Lorenzini L, et al. Continuous beta-amyloid CSF\/PET imbalance model to capture Alzheimer disease heterogeneity. Neurology. 2024;103(1):e209419. https:\/\/doi.org\/10.1212\/WNL.0000000000209419.","journal-title":"Neurology"},{"key":"879_CR161","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.872509","volume":"16","author":"B Chen","year":"2022","unstructured":"Chen B, Marquez-Nostra B, Belitzky E, Toyonaga T, Tong J, Huang Y, et al. PET imaging in animal models of Alzheimer\u2019s disease. Front Neurosci. 2022;16:872509. https:\/\/doi.org\/10.3389\/fnins.2022.872509.","journal-title":"Front Neurosci"},{"issue":"1","key":"879_CR162","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-026-00854-8","volume":"13","author":"SC Chiu","year":"2026","unstructured":"Chiu SC, Lin YC, McConathy J, Lin SY, Fang YD, Alzheimer\u2019s Disease Neuroimaging Initiative. Amyloid PET quantification with deep learning segmentation models without MRI. EJNMMI Phys. 2026;13(1):37. https:\/\/doi.org\/10.1186\/s40658-026-00854-8.","journal-title":"EJNMMI Phys"},{"issue":"1","key":"879_CR163","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-023-01363-x","volume":"15","author":"N Kimura","year":"2023","unstructured":"Kimura N, Aota T, Aso Y, Yabuuchi K, Sasaki K, Masuda T, et al. Predicting positron emission tomography brain amyloid positivity using interpretable machine learning models with wearable sensor data and lifestyle factors. Alzheimers Res Ther. 2023;15(1):212. https:\/\/doi.org\/10.1186\/s13195-023-01363-x.","journal-title":"Alzheimers Res Ther"}],"container-title":["Molecular Diagnosis &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00879-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-026-00879-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00879-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:18:09Z","timestamp":1789035489000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-026-00879-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":163,"alternative-id":["879"],"URL":"https:\/\/doi.org\/10.1007\/s40291-026-00879-w","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"11 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Luca Filippi receives institutional support through the\u00a0\n                      Ricerca Corrente\n                      \u00a0program of the Italian Ministry of Health. No specific funding was received for the preparation of this article, and no sponsor contributed to the open access fee.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Simone Lista, Luca Filippi, Enzo Emanuele, Susana L\u00f3pez-Ortiz, Giusy Ylenia Cisale, Piercarlo Minoretti, Francesco Garaci, and Alejandro Santos-Lozano have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SL: conceptualization; project administration; supervision; writing (original draft); writing (review and editing). LF: supervision; writing (original draft); writing (review and editing). EE: project administration; supervision; writing (original draft); writing (review and editing). SLO: writing (original draft); writing (review and editing). GYC: writing (original draft); writing (review and editing). PM: writing (original draft); writing (review and editing). FG: supervision; writing (original draft); writing (review and editing). AS-L: conceptualization; project administration; supervision; writing (original draft); writing (review and editing). All authors have read and approved the final version of the manuscript.","order":8,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}